Figure 3From: Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitorOverlay of 4E20 (beige) with previously reported structure 3LXN (rose): The overall structural fold is preserved when comparing the two structures with an r.m.s.d of 0.5 Å. Compound 1 is shown in orange.Back to article page